Health.Global Q2 FY27 Results (NSE: HCG)
Signal: Steady quarter
The read
The disclosed standalone trajectory is operationally positive on revenue, with revenue from operations at ₹39,604 lakh, +15.0% YoY and +5.5% QoQ, but earnings quality weakened: profit before exceptional items and tax fell 74.8% YoY to ₹368 lakh and a newly recognized ₹661 lakh customs-duty provision drove a ₹204 lakh loss. Consolidated momentum and margin cannot be assessed because the consolidated financial-results statement is absent from the supplied filing text.
P&L walk
Standalone revenue increased to ₹39,604 lakh, +15.0% YoY and +5.5% QoQ, but profit before exceptional items fell to ₹368 lakh, -74.8% YoY, and the ₹661 lakh customs-duty provision produced a ₹204 lakh loss versus ₹1,078 lakh profit a year earlier.
Key positives
- Standalone revenue from operations reached ₹39,604 lakh, growing +15.0% YoY and +5.5% QoQ.
- Property, plant and equipment increased to ₹74,171 lakh from ₹69,443 lakh at 31 March 2026, while CWIP rose to ₹1,980 lakh from ₹1,379 lakh.
- Standalone PAT and basic EPS moved in the same direction, with PAT at ₹(204) lakh and EPS at ₹(0.14), limiting evidence of a separate per-share dilution effect in the quarter.
Key concerns
- Profit before exceptional items and tax fell to ₹368 lakh, down 74.8% YoY, despite revenue growth of 15.0%.
- Employee benefits expense rose 32.6% YoY to ₹7,007 lakh, materially faster than revenue growth of 15.0%.
- H1 operating cash generation declined to ₹3,167 lakh from ₹11,023 lakh in H1FY26, despite H1 revenue increasing to ₹77,129 lakh from ₹67,034 lakh.
- The supplied text does not include the consolidated financial-results statement, preventing assessment of group revenue, EBITDA, PAT and segment contribution.
Research and educational content only. Not investment advice.